Trade

with

Arrowhead Research Corp
(NASDAQ: ARWR)
AdChoices
6.75
-0.05
-0.74%
After Hours :
6.82
+0.07
+1.04%

Open

6.94

Previous Close

6.80

Volume (Avg)

1.77M (4.64M)

Day's Range

6.72-7.12

52Wk Range

5.47-27.63

Market Cap.

357.13M

Dividend Rate ( Yield )

-

Beta

2.77

Shares Outstanding

52.91M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 290.27k

    • Net Income

    • -31.14M

    • Market Cap.

    • 357.13M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -28,509.68

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 2.77

    • Forward P/E

    • -6.60

    • Price/Sales

    • 1,666.67

    • Price/Book Value

    • 1.93

    • Price/Cash flow

    • -9.51

      • EBITDA

      • -22.84M

      • Return on Capital %

      • -41.91

      • Return on Equity %

      • -45.09

      • Return on Assets %

      • -41.91

      • Book Value/Share

      • 3.52

      • Shares Outstanding

      • 52.91M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 27.50

        • Credit Rating

        • -

        • Analysts

        • 2

        • EPS Estimate

        • -1.14

        • Cashflow Estimate

        • 0.36

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 0.00

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -25.94

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • -28,628.54

            • 39.38

            • Net Profit Margin

            • -28,509.68

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 100.00

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -5,522.50

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.00

              • 0.76

              • Current Ratio

              • 19.81

              • 2.92

              • Quick Ratio

              • 19.66

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • 1.06

              • 2.21

              • Book Value/Share

              • 3.52

              • 4.75

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -5.69

                • 277.78

                • P/E Ratio 5-Year High

                • -23.96

                • 634.30

                • P/E Ratio 5-Year Low

                • -1.43

                • 124.82

                • Price/Sales Ratio

                • 1,666.67

                • 9.35

                • Price/Book Value

                • 1.87

                • 8.50

                • Price/Cash Flow Ratio

                • -9.51

                • 50.25

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -45.09

                    (-137.60)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -41.91

                    (-96.10)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -44.41

                    (-121.40)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • 0.00

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -24.59M
                  Operating Margin
                  -8,471.29
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -9.51
                  Ownership

                  Institutional Ownership

                  85.59%

                  Top 10 Institutions

                  49.06%

                  Mutual Fund Ownership

                  29.46%

                  Float

                  99.88%

                  5% / Insider Ownership

                  2.37%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    3,179,395

                  • 0.00

                  • 6.01

                  • Franklin Biotechnology Discovery

                  •  

                    1,160,600

                  • 28.57

                  • 2.23

                  • SPDR® S&P Biotech ETF

                  •  

                    1,071,112

                  • 3.59

                  • 0.90

                  • Biotech Growth Trust Plc

                  •  

                    1,007,800

                  • 0.00

                  • 1.94

                  • Vanguard Total Stock Mkt Idx

                  •  

                    844,977

                  • 0.00

                  • 1.60

                  • iShares Russell 2000 (AU)

                  •  

                    801,036

                  • -1.02

                  • 0.67

                  • Fidelity® Select Health Care Portfolio

                  •  

                    800,000

                  • 0.00

                  • 1.51

                  • Fidelity Advisor® Biotechnology Fund

                  •  

                    553,155

                  • 0.00

                  • 1.05

                  • Parvest Equity USA Small Cap

                  •  

                    499,480

                  • 11.69

                  • 0.94

                  • Franklin Biotechnology Discovery Fund

                  •  

                    498,700

                  • 0.00

                  • 0.94

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity Management and Research Company

                  •  

                    5,003,850

                  • -9.37%

                  • 9.46

                  • Orbimed Advisors, LLC

                  •  

                    4,957,800

                  • +26.80%

                  • 9.37

                  • Qvt Financial LP

                  •  

                    4,030,882

                  • +96.84%

                  • 7.62

                  • State Street Corp

                  •  

                    1,875,705

                  • +138.91%

                  • 3.55

                  • Franklin Advisers, Inc.

                  •  

                    1,629,400

                  • -3.62%

                  • 3.08

                  • Vanguard Group, Inc.

                  •  

                    1,487,288

                  • +21.98%

                  • 2.81

                  • BlackRock Fund Advisors

                  •  

                    1,446,340

                  • +125.09%

                  • 2.73

                  • Baker Bros Advisors LLC

                  •  

                    1,430,802

                  • +95.45%

                  • 2.70

                  • Millennium Management LLC

                  •  

                    1,248,503

                  • -43.89%

                  • 2.36

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Distressed

                  Style

                  Small Growth

                  Arrowhead Research Corp was originally incorporated in South Dakota in 1989, and was reincorporated in Delaware in 2000. It is a biopharmaceutical company developing targeted RNAi therapeutics. The Company is leveraging its proprietary drug delivery technologies to develop drugs based on the RNA interference mechanism that efficiently silences disease-causing genes. Its pipeline includes clinical programs in chronic hepatitis B virus and partner-based programs in obesity and oncology. The product include ARC-520, Adipotide, CRLX-101, Tubulin Inhibitor.The drug products are regulated by FDA under the Federal Food, Drug and Cosmetic Act (the “FDCA”), and other laws within the Public Health Service Act.

                  Key People

                  Dr. Christopher Anzalone,PhD

                  CEO/Director/President

                  Dr. Douglass Given, PhD

                  Chairman of the Board/Director

                  Mr. Kenneth Myszkowski

                  CFO/Chief Accounting Officer

                  Mr. Charles P. McKenney

                  Director

                  Mr. Edward W. Frykman

                  Director

                  • Arrowhead Research Corp

                  • 225 South Lake Avenue

                  • Pasedena, CA 91101

                  • USA.Map

                  • Phone: +1 626 304-3400

                  • Fax: +1 626 304-3401

                  • arrowheadresearch.com

                  Incorporated

                  1989

                  Employees

                  54

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: